Saeed Aldarwish, Clemens Schafmayer, Sebastian Hinz
Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that can occur in the postoperative period, often mimicking surgical site infections (SSIs). The clinical overlap between PG and SSIs - including erythema, wound dehiscence, and purulent discharge - makes timely diagnosis challenging.
Case presentation: A 61-year-old female with a history of ovarian cancer and metachronous liver metastasis underwent an open left hemihepatectomy. On the fifth postoperative day, she developed erythema, wound dehiscence, and necrosis unresponsive to broad-spectrum antibiotics. Wound cultures remained sterile. Dermatologic consultation and histopathology confirmed the diagnosis of PG, characterized by dense neutrophilic infiltration and pyogenic folliculitis. High-dose corticosteroid therapy led to marked clinical improvement within 5 days, with full wound healing achieved by discharge.
Conclusion: Postoperative PG should be considered in non-resolving postoperative wound complications with negative cultures and antibiotic failure. In this context, prior exposure to PARP inhibitors may be a biologically plausible cofactor through immune modulation; however, a causal link remains unproven. Early dermatology consultation and biopsy are essential to avoid harmful debridement and expedite immunosuppression.
{"title":"Postoperative Pyoderma Gangrenosum: Rare Infection Mimic and Diagnostic Challenge - A Case Report.","authors":"Saeed Aldarwish, Clemens Schafmayer, Sebastian Hinz","doi":"10.1159/000550349","DOIUrl":"https://doi.org/10.1159/000550349","url":null,"abstract":"<p><strong>Background: </strong>Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that can occur in the postoperative period, often mimicking surgical site infections (SSIs). The clinical overlap between PG and SSIs - including erythema, wound dehiscence, and purulent discharge - makes timely diagnosis challenging.</p><p><strong>Case presentation: </strong>A 61-year-old female with a history of ovarian cancer and metachronous liver metastasis underwent an open left hemihepatectomy. On the fifth postoperative day, she developed erythema, wound dehiscence, and necrosis unresponsive to broad-spectrum antibiotics. Wound cultures remained sterile. Dermatologic consultation and histopathology confirmed the diagnosis of PG, characterized by dense neutrophilic infiltration and pyogenic folliculitis. High-dose corticosteroid therapy led to marked clinical improvement within 5 days, with full wound healing achieved by discharge.</p><p><strong>Conclusion: </strong>Postoperative PG should be considered in non-resolving postoperative wound complications with negative cultures and antibiotic failure. In this context, prior exposure to PARP inhibitors may be a biologically plausible cofactor through immune modulation; however, a causal link remains unproven. Early dermatology consultation and biopsy are essential to avoid harmful debridement and expedite immunosuppression.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12875664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Passing on the Baton: Ernst Klar Steps Down as Editor-in-Chief.","authors":"Georg Kaehler, Markus F Neurath, Jens Werner","doi":"10.1159/000550065","DOIUrl":"https://doi.org/10.1159/000550065","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-08DOI: 10.1159/000548686
Nina Eberhardt, Benedikt Haggenmüller
Background: Alveolar echinococcosis (AE) is a rare but potentially life-threatening parasitic disease caused by the larval stage of Echinococcus multilocularis, primarily affecting the liver with infiltrative, tumor-like growth. Sectional imaging plays a pivotal role in diagnosis, staging, and treatment planning. This study aimed to systematically evaluate the initial imaging findings in a cohort of patients with suspected AE, focusing on morphological and metabolic imaging features and their implications for staging and therapeutic decision-making.
Methods: We retrospectively analyzed all patients who presented with suspected AE at the University Hospital Ulm between January 2019 and December 2023 and had F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET/computed tomography [CT] or PET/ magnetic resonance imaging [MRI]) and/or MRI within 6 months of presentation. PET imaging was visually assessed for increased FDG uptake as a marker of metabolic activity. Lesions were classified according to the Kodama MRI classification. Imaging-based staging was performed using the PNM classification and compared with the clinical PNM stage.
Results: A total of 203 patients were included. PET imaging was performed in 198 cases (97.5%), while MRI was available in 94 patients (46.3%). Kodama types 2 (n = 30) and 3 (n = 55) were the most frequent lesion types. In the subgroup with both PET and MRI imaging (n = 89), PET activity was observed in 96.4% of Kodama type 2 and 90.6% of type 3 lesions, while no FDG uptake was noted in type 5 lesions. Imaging-based PNM classification disagreed with clinical staging in 56 cases (27.6%), likely due to standardized review by experienced radiologists and nuclear medicine specialists. PET/CT proved valuable for assessing extrahepatic and distant involvement, offering a whole-body evaluation that was more consistent than MRI, which often varied in protocol and anatomical coverage.
Conclusion: F-18-FDG-PET/CT is a cornerstone in the initial diagnostic workup and staging of AE, enabling both assessment of disease extent and evaluation of inflammatory activity in specialized centers. While MRI provides essential morphological details, its limited availability and heterogeneous acquisition protocols reduce its utility for comprehensive staging. Kodama lesion types correlate with metabolic activity, but further studies are needed to clarify their prognostic relevance. Our findings underscore the importance of standardized imaging protocols and the central role of PET/CT in managing newly diagnosed AE.
{"title":"Sectional Imaging for Alveolar Echinococcosis.","authors":"Nina Eberhardt, Benedikt Haggenmüller","doi":"10.1159/000548686","DOIUrl":"https://doi.org/10.1159/000548686","url":null,"abstract":"<p><strong>Background: </strong>Alveolar echinococcosis (AE) is a rare but potentially life-threatening parasitic disease caused by the larval stage of <i>Echinococcus multilocularis</i>, primarily affecting the liver with infiltrative, tumor-like growth. Sectional imaging plays a pivotal role in diagnosis, staging, and treatment planning. This study aimed to systematically evaluate the initial imaging findings in a cohort of patients with suspected AE, focusing on morphological and metabolic imaging features and their implications for staging and therapeutic decision-making.</p><p><strong>Methods: </strong>We retrospectively analyzed all patients who presented with suspected AE at the University Hospital Ulm between January 2019 and December 2023 and had F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET/computed tomography [CT] or PET/ magnetic resonance imaging [MRI]) and/or MRI within 6 months of presentation. PET imaging was visually assessed for increased FDG uptake as a marker of metabolic activity. Lesions were classified according to the Kodama MRI classification. Imaging-based staging was performed using the PNM classification and compared with the clinical PNM stage.</p><p><strong>Results: </strong>A total of 203 patients were included. PET imaging was performed in 198 cases (97.5%), while MRI was available in 94 patients (46.3%). Kodama types 2 (<i>n</i> = 30) and 3 (<i>n</i> = 55) were the most frequent lesion types. In the subgroup with both PET and MRI imaging (<i>n</i> = 89), PET activity was observed in 96.4% of Kodama type 2 and 90.6% of type 3 lesions, while no FDG uptake was noted in type 5 lesions. Imaging-based PNM classification disagreed with clinical staging in 56 cases (27.6%), likely due to standardized review by experienced radiologists and nuclear medicine specialists. PET/CT proved valuable for assessing extrahepatic and distant involvement, offering a whole-body evaluation that was more consistent than MRI, which often varied in protocol and anatomical coverage.</p><p><strong>Conclusion: </strong>F-18-FDG-PET/CT is a cornerstone in the initial diagnostic workup and staging of AE, enabling both assessment of disease extent and evaluation of inflammatory activity in specialized centers. While MRI provides essential morphological details, its limited availability and heterogeneous acquisition protocols reduce its utility for comprehensive staging. Kodama lesion types correlate with metabolic activity, but further studies are needed to clarify their prognostic relevance. Our findings underscore the importance of standardized imaging protocols and the central role of PET/CT in managing newly diagnosed AE.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"41 6","pages":"320-327"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-08DOI: 10.1159/000548843
Beate Gruener, Marko Kornmann
{"title":"Updating Clinical Management of Cystic and Alveolar Echinococcosis: Insights and Challenges.","authors":"Beate Gruener, Marko Kornmann","doi":"10.1159/000548843","DOIUrl":"https://doi.org/10.1159/000548843","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"41 6","pages":"307-309"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Introduction: </strong>Alveolar echinococcosis (AE) is a parasitic disease caused by the larval stage of <i>Echinococcus multilocularis</i> with increasing incidence in traditional prevalence areas of Central Europe and expanding to Eastern and Northern Europe. Primarily affecting the liver, AE can cause severe complications through invasive growth. Diagnosis involves clinical assessment, imaging, and serology. Lesions are surgically removed if possible; otherwise, long-term benzimidazole treatment is indicated. The study aimed to comprehensively analyze clinical, imaging, serological, and laboratory findings at initial diagnosis.</p><p><strong>Methods: </strong>The data of patients who first presented with AE to the outpatient clinic for infectious diseases at Ulm University Hospital between 1 January 2019 and 31 December 2023 were analyzed and compared to previous cohorts. Diagnostic imaging (whole-body fluoro-deoxyglucose positron emission tomography combined with CT or MRI if feasible or at least abdominal ultrasound) and laboratory tests (echinococcal serology, immunoglobulin E [IgE], liver parameters) were performed upon first admission. Liver lesion characteristics were assessed solely using imaging obtained at our clinic. Data on symptom presence, occurrence of incidental diagnoses, initial pharmacological treatment and assessment of potential curative operability were evaluated.</p><p><strong>Results: </strong>During the study period, 219 patients with AE (slight female majority, average age 56.7 years) made their first presentation, mainly from southeast Baden-Württemberg (<i>n</i> = 68) and southwest Bavaria (<i>n</i> = 90). Most presented in advanced WHO stage IV (38.2%), with 43% showing lesions extending into organs neighboring the liver. Case definition and WHO stage showed a significant relationship (χ<sup>2</sup>[8, <i>N</i> = 217] = 30.2, <i>p</i> < 0.01, V = 0.26). A negative correlation was observed between lesion number and size, whereby larger lesions (above the average lesion size of 66.6 mm) were indicative of higher WHO stages (stages III and IV) (<i>r</i> <sub><i>s</i></sub> -0.22, <i>p</i> = 0.02). Higher WHO stages and larger lesions were associated with elevated IgE levels and positive echinococcal serology. Furthermore, they correlated with higher values of ALT (<i>r</i> <sub><i>p</i></sub> = 0.2, <i>p</i> < 0.02), AP (<i>r</i> <sub><i>p</i></sub> = 0.18, <i>p</i> < 0.04) and γGT (<i>r</i> <sub><i>p</i></sub> = 0.27, <i>p</i> < 0.01). The most frequent and highest elevation was seen in γGT. Over half (<i>n</i> = 118, 53.9%) were asymptomatic at diagnosis; an increasing lesion size was more frequently associated with symptoms. The diagnosis was an incidental finding in 55.5%. Albendazole was the initial drug therapy for all patients. Surgery with curative intent was considered feasible in 42.7%, predominantly at lower WHO stages and single-lobe involvement.</p><p><strong>Conclusion: </strong>Compared to pre
肺泡棘球蚴病(AE)是一种由多房棘球蚴幼虫期引起的寄生虫病,在中欧传统流行地区发病率不断上升,并向东欧和北欧扩展。AE主要影响肝脏,可通过侵入性生长引起严重的并发症。诊断包括临床评估、影像学和血清学。如果可能,通过手术切除病变;否则,需要长期苯并咪唑治疗。该研究旨在综合分析临床、影像学、血清学和实验室的初步诊断结果。方法:分析2019年1月1日至2023年12月31日期间在乌尔姆大学医院传染病门诊首次出现AE的患者的数据,并与之前的队列进行比较。首次入院时进行诊断成像(全身荧光脱氧葡萄糖正电子发射断层扫描结合CT或MRI,如果可行,或至少腹部超声)和实验室检查(棘球蚴血清学、免疫球蛋白E [IgE]、肝脏参数)。肝脏病变特征仅使用在我们诊所获得的影像进行评估。对两组患者的症状表现、意外诊断、初始药物治疗及潜在治疗可操作性进行评估。结果:研究期间首次出现AE患者219例,女性占多数,平均年龄56.7岁,主要来自巴登-符腾堡州东南部(n = 68)和巴伐利亚西南部(n = 90)。大多数出现在世卫组织晚期IV期(38.2%),其中43%显示病变扩展到肝脏附近的器官。病例定义与WHO分期呈显著相关(χ2[8, N = 217] = 30.2, p < 0.01, V = 0.26)。病变数量与大小呈负相关,较大的病变(大于平均66.6 mm)表明WHO分级较高(III期和IV期)(r s -0.22, p = 0.02)。较高的WHO分期和较大的病变与IgE水平升高和棘球蚴血清学阳性相关。与ALT (r p = 0.2, p < 0.02)、AP (r p = 0.18, p < 0.04)、γ - gt (r p = 0.27, p < 0.01)升高相关。γ - gt出现频率最高,海拔最高。超过一半(n = 118, 53.9%)在诊断时无症状;病变大小的增加更常与症状相关。55.5%为偶然发现。阿苯达唑是所有患者的初始药物治疗。42.7%的患者认为有治疗目的的手术是可行的,主要是WHO分期较低和单叶受累者。结论:与以前的临床队列相比,每年AE病例数稳步增加,并具有持续的地理聚类。这表明AE的重要性将继续增加。该研究概述了AE的初步诊断情况,并表明在门诊治疗的患者应将其视为鉴别诊断。WHO分期分布保持一致,但无症状和偶发病例明显增加,强调了常规腹部超声在初级保健中的扩大使用和AE意识的重要性。较大的病变与症状、IgE升高和棘球蚴阳性血清学相关——两者都是疾病活动性增加和预后较差的指标。因此,病变直径,总IgE和血清学应纳入疾病分期和决定手术切除。特别是在有症状的患者和WHO分期较高的患者中,AE主要导致胆汁淤积参数升高,这反映出胆道流出梗阻,并与较差的预后相关。对于不明原因胆汁淤积的门诊患者,这些发现应该是考虑AE的原因。
{"title":"Clinical, Diagnostical, and Epidemiological Findings at First Diagnosis of Alveolar Echinococcosis: A Single-Center Cohort Study.","authors":"Anna-Lena Allgäuer, Lynn Peters, Alexander Grunenberg, Wanjie Jiang, Dominik Trautmann, Camilla Westerwinter, Beate Grüner","doi":"10.1159/000548684","DOIUrl":"https://doi.org/10.1159/000548684","url":null,"abstract":"<p><strong>Introduction: </strong>Alveolar echinococcosis (AE) is a parasitic disease caused by the larval stage of <i>Echinococcus multilocularis</i> with increasing incidence in traditional prevalence areas of Central Europe and expanding to Eastern and Northern Europe. Primarily affecting the liver, AE can cause severe complications through invasive growth. Diagnosis involves clinical assessment, imaging, and serology. Lesions are surgically removed if possible; otherwise, long-term benzimidazole treatment is indicated. The study aimed to comprehensively analyze clinical, imaging, serological, and laboratory findings at initial diagnosis.</p><p><strong>Methods: </strong>The data of patients who first presented with AE to the outpatient clinic for infectious diseases at Ulm University Hospital between 1 January 2019 and 31 December 2023 were analyzed and compared to previous cohorts. Diagnostic imaging (whole-body fluoro-deoxyglucose positron emission tomography combined with CT or MRI if feasible or at least abdominal ultrasound) and laboratory tests (echinococcal serology, immunoglobulin E [IgE], liver parameters) were performed upon first admission. Liver lesion characteristics were assessed solely using imaging obtained at our clinic. Data on symptom presence, occurrence of incidental diagnoses, initial pharmacological treatment and assessment of potential curative operability were evaluated.</p><p><strong>Results: </strong>During the study period, 219 patients with AE (slight female majority, average age 56.7 years) made their first presentation, mainly from southeast Baden-Württemberg (<i>n</i> = 68) and southwest Bavaria (<i>n</i> = 90). Most presented in advanced WHO stage IV (38.2%), with 43% showing lesions extending into organs neighboring the liver. Case definition and WHO stage showed a significant relationship (χ<sup>2</sup>[8, <i>N</i> = 217] = 30.2, <i>p</i> < 0.01, V = 0.26). A negative correlation was observed between lesion number and size, whereby larger lesions (above the average lesion size of 66.6 mm) were indicative of higher WHO stages (stages III and IV) (<i>r</i> <sub><i>s</i></sub> -0.22, <i>p</i> = 0.02). Higher WHO stages and larger lesions were associated with elevated IgE levels and positive echinococcal serology. Furthermore, they correlated with higher values of ALT (<i>r</i> <sub><i>p</i></sub> = 0.2, <i>p</i> < 0.02), AP (<i>r</i> <sub><i>p</i></sub> = 0.18, <i>p</i> < 0.04) and γGT (<i>r</i> <sub><i>p</i></sub> = 0.27, <i>p</i> < 0.01). The most frequent and highest elevation was seen in γGT. Over half (<i>n</i> = 118, 53.9%) were asymptomatic at diagnosis; an increasing lesion size was more frequently associated with symptoms. The diagnosis was an incidental finding in 55.5%. Albendazole was the initial drug therapy for all patients. Surgery with curative intent was considered feasible in 42.7%, predominantly at lower WHO stages and single-lobe involvement.</p><p><strong>Conclusion: </strong>Compared to pre","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"41 6","pages":"310-319"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Echinococcosis is a parasitic disease, caused by the larval stage of the genus Echinococcus. Echinococcusmultilocularis and Echinococcus granulosus cause alveolar echinococcosis (AE) and cystic echinococcosis (CE) in humans. Pathologists may be confronted with the larval stage of both species. Diagnosis may be difficult due to the low incidence in daily routine. However, right diagnosis of the pathologist is still the gold standard and crucial for further treatment of the patient.
Summary: Macroscopically, specimens of AE show multiple small cysts and a bread-like appearance. Instead, CE manifests as solitary or multiple grape-like cysts. In this review, we give a short algorithm for the differential diagnosis on histological grounds. Hematoxylin and eosin staining is supported by an additional periodic acid-Schiff (PAS) staining, highlighting the laminated layer (LL) as key microscopic structure. Lymphocytes and fibrosis are present at the interface with the adjoining liver tissue. The main difference lies in the morphology of the LL. In the PAS staining, this deeply violet structure is fragmented and thin in AE, while in CE, it is broad and striated. Further important characteristics are the size of the cysts and the pericystic fibrosis. The different types of CT lesions correspond to different histological features. Treatment with benzimidazoles may influence morphology. Immunohistochemistry (IHC) with the monoclonal antibodies (mAbs) EmG3 and Em2G11 shows differences in staining patterns regarding AE and CE. IHC is decisive to settle the diagnosis in unclear situations and when only small particles of E. multilocularis (SPEMS) or E. granulosus (SPEGS) are present, e.g., in lymph nodes.
Key messages: The PAS-positive LL is the microscopic hallmark for the differential diagnosis of AE/CE. For further support in unclear situations, IHC with mAb EmG3 and mAb Em2G11 is advised.
{"title":"Macroscopic and Microscopic Aspects of <i>Echinococcus multilocularis</i> and <i>Echinococcus granulosus</i> in Humans: A Guideline for Pathologists.","authors":"Hanspeter Frey, Thomas F E Barth","doi":"10.1159/000548706","DOIUrl":"10.1159/000548706","url":null,"abstract":"<p><strong>Background: </strong>Echinococcosis is a parasitic disease, caused by the larval stage of the genus <i>Echinococcus</i>. <i>Echinococcus</i> <i>multilocularis</i> and <i>Echinococcus granulosus</i> cause alveolar echinococcosis (AE) and cystic echinococcosis (CE) in humans. Pathologists may be confronted with the larval stage of both species. Diagnosis may be difficult due to the low incidence in daily routine. However, right diagnosis of the pathologist is still the gold standard and crucial for further treatment of the patient.</p><p><strong>Summary: </strong>Macroscopically, specimens of AE show multiple small cysts and a bread-like appearance. Instead, CE manifests as solitary or multiple grape-like cysts. In this review, we give a short algorithm for the differential diagnosis on histological grounds. Hematoxylin and eosin staining is supported by an additional periodic acid-Schiff (PAS) staining, highlighting the laminated layer (LL) as key microscopic structure. Lymphocytes and fibrosis are present at the interface with the adjoining liver tissue. The main difference lies in the morphology of the LL. In the PAS staining, this deeply violet structure is fragmented and thin in AE, while in CE, it is broad and striated. Further important characteristics are the size of the cysts and the pericystic fibrosis. The different types of CT lesions correspond to different histological features. Treatment with benzimidazoles may influence morphology. Immunohistochemistry (IHC) with the monoclonal antibodies (mAbs) EmG3 and Em2G11 shows differences in staining patterns regarding AE and CE. IHC is decisive to settle the diagnosis in unclear situations and when only small particles of <i>E. multilocularis</i> (SPEMS) or <i>E. granulosus</i> (SPEGS) are present, e.g., in lymph nodes.</p><p><strong>Key messages: </strong>The PAS-positive LL is the microscopic hallmark for the differential diagnosis of AE/CE. For further support in unclear situations, IHC with mAb EmG3 and mAb Em2G11 is advised.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ronaldo A González García, Miriam Riedel, Adrian P Regensburger, Aline Rückel, Alexander Schnell, Marion Appel, Jan Thomas Schaefer, Carol-Immanuel Geppert, Joachim Woelfle, André Hoerning
Introduction: Hirschsprung's disease is a congenital anomaly affecting intestinal motility. Its main characteristic is the absence of ganglion cells in the distal colon, which results in chronic constipation. To date, confirmatory biopsies in the pediatric population have been obtained through suction biopsies or open surgical procedures. Therapeutic endoscopic full-thickness resection (EFTR) has been successfully used in adult endoscopy to treat various diseases of the lower gastrointestinal tract. This procedure has been shown to be safe and effective.
Methods: A single-center retrospective case series study from May 2024 to September 2025, including 13 pediatric patients aged 3.5-14.4 years (median 9.5 years) with therapy-refractory constipation, who underwent an EFTR biopsy using Ovesco diagnostic FTRD® as part of the diagnostic workup for Hirschsprung's disease. EFTR was performed in the distal rectum, 2 cm above the linea dentata, to exclude an ultrashort variant of Hirschsprung's disease.
Results: All EFTR procedures were successful, and only 1 patient had non-hemodynamically relevant rectal bleeding during the 1-year follow-up. All biopsies fulfilled the requirements to validate or exclude Hirschsprung's disease, showing an excellent success rate of full-thickness resection (100%).
Conclusions: This is the first case series of EFTR using the Ovesco diagnostic FTRD® technique in pediatric patients for the diagnosis of Hirschsprung's disease. EFTR is a safe, time-saving, and successful method that can be used to diagnose Hirschsprung's disease in pediatric patients starting from 3 years of age.
{"title":"Endoscopic Full-Thickness Resection Biopsy Using Ovesco Diagnostic FTRD® as a Tool to Diagnose Hirschsprung's Disease in Children: A Case Series.","authors":"Ronaldo A González García, Miriam Riedel, Adrian P Regensburger, Aline Rückel, Alexander Schnell, Marion Appel, Jan Thomas Schaefer, Carol-Immanuel Geppert, Joachim Woelfle, André Hoerning","doi":"10.1159/000549052","DOIUrl":"10.1159/000549052","url":null,"abstract":"<p><strong>Introduction: </strong>Hirschsprung's disease is a congenital anomaly affecting intestinal motility. Its main characteristic is the absence of ganglion cells in the distal colon, which results in chronic constipation. To date, confirmatory biopsies in the pediatric population have been obtained through suction biopsies or open surgical procedures. Therapeutic endoscopic full-thickness resection (EFTR) has been successfully used in adult endoscopy to treat various diseases of the lower gastrointestinal tract. This procedure has been shown to be safe and effective.</p><p><strong>Methods: </strong>A single-center retrospective case series study from May 2024 to September 2025, including 13 pediatric patients aged 3.5-14.4 years (median 9.5 years) with therapy-refractory constipation, who underwent an EFTR biopsy using Ovesco diagnostic FTRD® as part of the diagnostic workup for Hirschsprung's disease. EFTR was performed in the distal rectum, 2 cm above the linea dentata, to exclude an ultrashort variant of Hirschsprung's disease.</p><p><strong>Results: </strong>All EFTR procedures were successful, and only 1 patient had non-hemodynamically relevant rectal bleeding during the 1-year follow-up. All biopsies fulfilled the requirements to validate or exclude Hirschsprung's disease, showing an excellent success rate of full-thickness resection (100%).</p><p><strong>Conclusions: </strong>This is the first case series of EFTR using the Ovesco diagnostic FTRD® technique in pediatric patients for the diagnosis of Hirschsprung's disease. EFTR is a safe, time-saving, and successful method that can be used to diagnose Hirschsprung's disease in pediatric patients starting from 3 years of age.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-01-09DOI: 10.1159/000543479
Salman Khan
Background: Pancreatic cancer remains the fourth leading cause of cancer-related deaths in the USA despite its lower incidence, primarily due to late-stage diagnosis. While early detection could double survival rates, screening the general population is not cost-effective due to low disease prevalence and technical limitations.
Summary: This review examines the relationship between diabetes and pancreatic cancer, highlighting how diabetes types differently impact cancer risk. New-onset diabetes triples pancreatic cancer risk compared to the general population, while long-standing diabetes doubles it. Several prediction models have been developed to identify high-risk individuals among new-onset diabetes patients, with recent models achieving AUCs up to 0.91. Current biomarkers like CA 19-9 show improved utility when combined with other clinical parameters, though they remain inadequate for general population screening. Cost-effectiveness analysis suggests that screening becomes viable when 3-year cancer incidence exceeds 2% and 25% of cases are detected at a localized stage.
Key messages: (1) New-onset diabetes presents a stronger risk factor for pancreatic cancer than long-standing diabetes. (2) Multiple prediction models show promise but face challenges with missing data and cross-population validation. (3) Integrated approaches combining clinical parameters, biomarkers, and machine learning offer the most promising path forward for early detection. (4) Current detection rates fall below cost-effectiveness thresholds, highlighting the need for improved screening strategies.
{"title":"Prediction of Pancreatic Cancer Risk in Patients with New-Onset Diabetes.","authors":"Salman Khan","doi":"10.1159/000543479","DOIUrl":"10.1159/000543479","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer remains the fourth leading cause of cancer-related deaths in the USA despite its lower incidence, primarily due to late-stage diagnosis. While early detection could double survival rates, screening the general population is not cost-effective due to low disease prevalence and technical limitations.</p><p><strong>Summary: </strong>This review examines the relationship between diabetes and pancreatic cancer, highlighting how diabetes types differently impact cancer risk. New-onset diabetes triples pancreatic cancer risk compared to the general population, while long-standing diabetes doubles it. Several prediction models have been developed to identify high-risk individuals among new-onset diabetes patients, with recent models achieving AUCs up to 0.91. Current biomarkers like CA 19-9 show improved utility when combined with other clinical parameters, though they remain inadequate for general population screening. Cost-effectiveness analysis suggests that screening becomes viable when 3-year cancer incidence exceeds 2% and 25% of cases are detected at a localized stage.</p><p><strong>Key messages: </strong>(1) New-onset diabetes presents a stronger risk factor for pancreatic cancer than long-standing diabetes. (2) Multiple prediction models show promise but face challenges with missing data and cross-population validation. (3) Integrated approaches combining clinical parameters, biomarkers, and machine learning offer the most promising path forward for early detection. (4) Current detection rates fall below cost-effectiveness thresholds, highlighting the need for improved screening strategies.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"41 5","pages":"254-261"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Although they are evaluated in the same disease spectrum, the physiopathologies, diagnoses, treatment management strategies, and prognoses of AE and CE differ completely. Management of both diseases requires a multidisciplinary approach involving many branches such as surgery, interventional radiology, gastroenterology, anesthesia, and infectious diseases. The technical success of any AE or CE treatment depends largely on the technical skills and experience of the surgeon, gastroenterologist, or interventional radiologist, but the clinical success of the treatment depends on multidisciplinary collaboration to prevent and manage complications.
Summary: For liver CE, successful treatment results is achieved through three established percutaneous techniques The evaluation of percutaneous treatment outcomes should be based on the types of liver CE cysts, categorized into two groups according to the World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) classification: the first group includes CE1 and CE3a, while the second group encompasses CE2 and CE3b. Liver CE1 and CE3a cysts are treated using either Puncture, Aspiration, Injection, Reaspiration (PAIR) or catheterization techniques, with success rates reaching as high as 96% and recurrence rates as low as 4%. Modified catheterization (Mo-CAT) technique is a highly effective, safe, and successful option for treating CE2 and CE3b liver cysts. Although percutaneous interventional radiologic techniques have largely taken the place of surgery in treating patients with liver CE, radical surgery is the only cure option for AE. Partial hepatectomy or liver transplantation constitutes the primary therapeutic approach. Nevertheless, owing to the insidious nature of disease progression, diagnosis frequently occurs at an unresectable stage. In such instances, involvement of the biliary ducts and vascular structures, along with central necrosis of the lesion, may give rise to severe complications, including cholangitis, hepatic abscesses, portal hypertension, Budd-Chiari syndrome, biliary cirrhosis, and secondary infections, all of which can adversely affect both morbidity and mortality. Interventional radiologist is responsible for diagnosing the disease using radiological imaging methods (such as ultrasound, BT, and MRI), performing imaging-guided biopsy for definitive diagnosis, evaluating the resectability, managing both pre and postoperative biliary/vascular complications, and finally monitoring the disease progress.
Key messages: Liver CE management: percutaneous techniques such as PAIR or standard catheterization are preferred as first choice for treating CE1 and CE3a cysts. CE2 and CE3b (Gharbi type III) cysts can be treated with Mo-CAT technique as an alternative to surgery. Liver AE management: radical surgery is curative, but interventional radiology provides critical palliative care and enhances the
{"title":"The Role of Interventional Radiology for the Treatment of Liver CE and AE Lesions: Current Concepts.","authors":"Okan Akhan, Turkmen Ciftci","doi":"10.1159/000547623","DOIUrl":"10.1159/000547623","url":null,"abstract":"<p><strong>Background: </strong>Although they are evaluated in the same disease spectrum, the physiopathologies, diagnoses, treatment management strategies, and prognoses of AE and CE differ completely. Management of both diseases requires a multidisciplinary approach involving many branches such as surgery, interventional radiology, gastroenterology, anesthesia, and infectious diseases. The technical success of any AE or CE treatment depends largely on the technical skills and experience of the surgeon, gastroenterologist, or interventional radiologist, but the clinical success of the treatment depends on multidisciplinary collaboration to prevent and manage complications.</p><p><strong>Summary: </strong>For liver CE, successful treatment results is achieved through three established percutaneous techniques The evaluation of percutaneous treatment outcomes should be based on the types of liver CE cysts, categorized into two groups according to the World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) classification: the first group includes CE1 and CE3a, while the second group encompasses CE2 and CE3b. Liver CE1 and CE3a cysts are treated using either Puncture, Aspiration, Injection, Reaspiration (PAIR) or catheterization techniques, with success rates reaching as high as 96% and recurrence rates as low as 4%. Modified catheterization (Mo-CAT) technique is a highly effective, safe, and successful option for treating CE2 and CE3b liver cysts. Although percutaneous interventional radiologic techniques have largely taken the place of surgery in treating patients with liver CE, radical surgery is the only cure option for AE. Partial hepatectomy or liver transplantation constitutes the primary therapeutic approach. Nevertheless, owing to the insidious nature of disease progression, diagnosis frequently occurs at an unresectable stage. In such instances, involvement of the biliary ducts and vascular structures, along with central necrosis of the lesion, may give rise to severe complications, including cholangitis, hepatic abscesses, portal hypertension, Budd-Chiari syndrome, biliary cirrhosis, and secondary infections, all of which can adversely affect both morbidity and mortality. Interventional radiologist is responsible for diagnosing the disease using radiological imaging methods (such as ultrasound, BT, and MRI), performing imaging-guided biopsy for definitive diagnosis, evaluating the resectability, managing both pre and postoperative biliary/vascular complications, and finally monitoring the disease progress.</p><p><strong>Key messages: </strong>Liver CE management: percutaneous techniques such as PAIR or standard catheterization are preferred as first choice for treating CE1 and CE3a cysts. CE2 and CE3b (Gharbi type III) cysts can be treated with Mo-CAT technique as an alternative to surgery. Liver AE management: radical surgery is curative, but interventional radiology provides critical palliative care and enhances the","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edoardo Forcignanò, Mauro Verra, Giacomo Lo Secco, Alberto Arezzo
Background: Anastomotic leaks and fistulas are a feared and challenging postoperative complication in colorectal surgery. Traditionally managed with protective ileostomy and revisional surgery, less-invasive endoscopic approaches are increasingly being utilized.
Summary: This article provides a comprehensive overview of current endoscopic treatment principles for managing anastomotic leaks after colorectal surgery. These approaches can be categorized into three main strategies: endoscopic negative pressure therapy - using negative pressure via polyurethane foam drains to promote wound healing and drain secretions; direct closure techniques - including endoscopic suturing systems (e.g., OverStitch) and clipping devices (e.g., over-the-scope clip) to approximate tissue and close defects; and vacuum stenting - a hybrid approach that combines negative pressure therapy with defect coverage using a covered self-expanding metal mesh stent (VAC-stent). Each method offers unique advantages depending on the leak characteristics and timing of detection. Early diagnosis and individualized treatment selection are critical to successful outcomes.
Key messages: Endoscopic treatment of anastomotic insufficiencies represents a minimally invasive, effective and safe alternative to traditional surgical interventions, particularly in clinically stable patients.
{"title":"Endoscopic Management of Anastomotic Insufficiencies in the Lower GI Tract.","authors":"Edoardo Forcignanò, Mauro Verra, Giacomo Lo Secco, Alberto Arezzo","doi":"10.1159/000547021","DOIUrl":"10.1159/000547021","url":null,"abstract":"<p><strong>Background: </strong>Anastomotic leaks and fistulas are a feared and challenging postoperative complication in colorectal surgery. Traditionally managed with protective ileostomy and revisional surgery, less-invasive endoscopic approaches are increasingly being utilized.</p><p><strong>Summary: </strong>This article provides a comprehensive overview of current endoscopic treatment principles for managing anastomotic leaks after colorectal surgery. These approaches can be categorized into three main strategies: <i>endoscopic negative pressure therapy</i> - using negative pressure via polyurethane foam drains to promote wound healing and drain secretions; <i>direct closure techniques</i> - including endoscopic suturing systems (e.g., OverStitch) and clipping devices (e.g., over-the-scope clip) to approximate tissue and close defects; and <i>vacuum stenting</i> - a hybrid approach that combines negative pressure therapy with defect coverage using a covered self-expanding metal mesh stent (VAC-stent). Each method offers unique advantages depending on the leak characteristics and timing of detection. Early diagnosis and individualized treatment selection are critical to successful outcomes.</p><p><strong>Key messages: </strong>Endoscopic treatment of anastomotic insufficiencies represents a minimally invasive, effective and safe alternative to traditional surgical interventions, particularly in clinically stable patients.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}